Exelixis
EXEL
#1458
Rank
ยฃ11.20 B
Marketcap
ยฃ45.23
Share price
1.42%
Change (1 day)
55.74%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of October 2026 (TTM): 6.13

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.10. At the end of 2026 the company had a P/S ratio of 5.65.

P/S ratio history for Exelixis from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20265.6511.77%
20255.0613.58%
20244.459.22%
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
6.42 4.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.53-58.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
5.92-3.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
1.69-72.38%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
5.43-11.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.48-59.61%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
2.11-65.60%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
0.3770-93.85%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
5.53-9.80%๐Ÿ‡บ๐Ÿ‡ธ USA